 |
인쇄하기
취소
|
Sprycel price adjustment plan draws strong protest
The government plan to adjust the insurance price of BMS Korea's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, is drawing from leukemia patients, according to the Ministry of Health, Welfare and Family Affairs.
The ministry's insurance coordination committee failed to convene in April 11 due to strong rallies by leukemia patients and member of civic groups.
They arg...
The ministry's insurance coordination committee failed to convene in April 11 due to strong rallies by leukemia patients and member of civic groups.
They arg...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.